| Literature DB >> 34947859 |
Angelika V Timofeeva1, Ivan S Fedorov1, Maria A Shamina2, Vitaliy V Chagovets3, Nataliya P Makarova2, Elena A Kalinina2, Tatiana A Nazarenko4, Gennady T Sukhikh4.
Abstract
Despite the improvements in biotechnological approaches and the selection of controlled ovarian hyperstimulation protocols, the resulting pregnancy rate from in vitro fertilization (IVF) protocols still does not exceed 30-40%. In this connection, there is an acute question of the development of a non-invasive, sensitive, and specific method for assessing the implantation potential of an embryo. A total of 110 subfertile couples were included in the study to undergo the IVF/ICSI program. Obtained embryos for transfer into the uterine cavity of patient cohort 1 (n = 60) and cohort 2 (n = 50) were excellent/good-quality blastocysts, and small noncoding RNA (sncRNA) content in the corresponding spent culture medium samples at the morula stage (n = 43) or at the blastocyst stage (n = 31) was analyzed by deep sequencing followed by qRT-PCR in real time. Two logistic regression models were developed to predict the implantation potential of the embryo with 100% sensitivity and 100% specificity: model 1 at the morula stage, using various combinations of hsa_piR_022258, hsa-let-7i-5p, hsa_piR_000765, hsa_piR_015249, hsa_piR_019122, and hsa_piR_008112, and model 2 at the blastocyst stage, using various combinations of hsa_piR_020497, hsa_piR_008113, hsa-miR-381-3p, hsa_piR_022258, and hsa-let-7a-5p. Protein products of sncRNA potential target genes participate in the selective turnover of proteins through the ubiquitination system and in the organization of the various cell cytoskeleton and nucleoskeleton structures, regulating the activity of the Hippo signaling pathway, which determines the fate specification of the blastomers.Entities:
Keywords: blastocyst; deep sequencing; logistic regression model; miRNA; morula; piRNA; qRT-PCR; sncRNA gene-target
Year: 2021 PMID: 34947859 PMCID: PMC8706231 DOI: 10.3390/life11121328
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Figure 1Flow diagram of the experimental design.
sncRNA sequence data.
| sncRNA 1 | Accession Number 1 | Nucleotide Sequence of Sense Primer for PCR, 5′-3′ | PCR Primers Annealing Temperature, °C |
|---|---|---|---|
| hsa_piR_001312 | DQ571813 | attggtggttcagtggtagaattctcgcctg | 46.2 |
| hsa_piR_002769 | DQ573726 | tcataagtgggagctaaatgatgagaac | 46.2 |
| hsa_piR_008113 | DQ581032 | tgaggtagtaggttgtatagttttagggtc | 46.2 |
| hsa_piR_016240 | DQ592148 | tgttaaccgaaaggttggtggttcgagcc | 48.9 |
| hsa_piR_016742 | DQ593049 | ccggctagctcagtcggtagagcatgaga | 48.9 |
| hsa_piR_019122 | DQ596252 | gacagagaaaacaaggtggtgaactatgccc | 46.2 |
| hsa_piR_020365 | DQ597975 | ggccgtgatcgtatagtggttagtactctg | 46.2 |
| hsa_piR_000765 | DQ570956 | agcattggtggttcagtggtagaattctcgc | 49 |
| hsa_piR_000807 | DQ571005 | agcctgatgatgtcctcctccagttgccgc | 53 |
| hsa_piR_004695 | DQ576442 | tcctggaccagcctgatgatgtcctcctcc | 57 |
| hsa_piR_004880 | DQ576715 | tccttgtcctggaccagcctgatgatgtcct | 45 |
| hsa_piR_008112 | DQ581031 | tgaggtagtagattgtatagttgtggggtagt | 46.2 |
| hsa_piR_015026 | DQ590548 | tggttcagtggtagaattctcgcctcc | 45 |
| hsa_piR_015249 | DQ590830 | tgtagtcgtggccgagtggttaaggc | 46.2 |
| hsa_piR_015462 | DQ591122 | tgtcctgggccagcctgatgatgtcctcctc | 45 |
| hsa_piR_016735 | DQ593039 | ccgcctgggaataccgggtgctgtaggctta | 50 |
| hsa_piR_017716 | DQ594453 | ttccctggtggtctagtggttaggattcggc | 45 |
| hsa_piR_020381 | DQ597997 | ggcgggagtaactatgactctcttaaggta | 53 |
| hsa_piR_020485 | DQ598159 | ggggatgtagctcagtggtagagcgcatgct | 53 |
| hsa_piR_020497 | DQ598177 | tgtagctcagtggtagagcgcgtgct | 45 |
| hsa_piR_022258 | DQ600471 | tactacctgattggtcgggtgtgagc | 48.9 |
| hsa_piR_022628 | DQ600952 | tagagcatgagactcttaatctcagggtcgtg | 48.9 |
| hsa_piR_020388 | DQ598008 | ggctcgttggtctaggggtatgattctcgg | 45 |
| hsa-miR-381-3p | MIMAT0000736 | tatacaagggcaagctctctgt | 52.7 |
| hsa-let-7a-5p | MIMAT0000062 | Hs_let-7a_2 miScript Primer Assay, MS00031220 | 55 |
| hsa-let-7b-5p | MIMAT0000063 | Hs_let-7b_1 miScript Primer Assay, MS00003122 | 55 |
| hsa-let-7i-5p | MIMAT0000415 | Hs_let-7i_1 miScript Primer Assay, MS00003157 | 55 |
1 piRNAbank (http://pirnabank.ibab.ac.in/cgi-bin/accession.cgi, last accessed on 15 June 2021) for piRNAs; miRBase (http://www.mirbase.org/search.shtml, last accessed on 15 June 2021) for miRNAs.
Comparative characteristics of clinical data and parameters of the IVF/ICSI protocol in couples, depending on the outcome of the ART program.
| Clinical Data and Parameters of the IVF/ICSI Protocol | Negative Outcome ( | Positive Outcome ( | Mann–Whitney Test, |
|---|---|---|---|
| Me (Q1;Q3) 1 | |||
| Age of Female | 32.5 (30;35) | 31 (30;32.75) | 0.112915 |
| Menarche, age | 13 (13;14) | 13 (13;14) | 0.941626 |
| Duration of menstrual bleeding, days | 5 (4;5) | 4 (4;5) | 0.195459 |
| The length of the menstrual cycle, days | 28 (28;30) | 28 (28;29.75) | 0.256809 |
| Prolactin (120.0–500.0, mIU/L) | 301.2 (198.55;352.75) | 284.35 (194.25;337.57) | 0.473241 |
| 17-OH-progesterone (0.3–3.0, nmole/L) | 1.58 (1.1;1.96) | 1.3 (1.22;1.65) | 0.538915 |
| Dehydroepiandrosterone sulphate (0.9–11.7, µmole/L) | 5.2 (3.1;7.6) | 3.45 (2.45;6.8) | 0.283792 |
| Cortisol (200.0–550.0, nmole/L) | 315 (245.05;380.5) | 306.15 (259.55;373.3) | 0.901587 |
| Testosterone (0.5–2.5, nmole/L) | 1.61 (1.12;2) | 1.15 (0.74;1.67) | 0.017549 |
| Anti-müllerian hormone (1.0–10.6, ng/mL) | 2.21 (1.52;3.1) | 3.05 (2.35;4.33) | 0.007737 |
| Thyroid-stimulating hormone (0.4–3.5, mIU/L) | 1.77 (1.15;2.49) | 1.27 (0.98;2.14) | 0.182973 |
| Free thyroxine (10.0–25.0, pmole/L) | 15.1 (12.22;18) | 14.75 (12.06;18.3) | 0.950685 |
| Luteinizing hormone (2.3–15.0, IU/L) | 5.9 (4.75;7.08) | 4.8 (4.15;5.74) | 0.036986 |
| Progesterone, luteal phase of the menstrual cycle (16.0–95.0, nmole/L) | 27.6 (19.02;43) | 31.58 (24.05;47) | 0.251808 |
| Follicle-stimulating hormone (2.0–10.0, IU/L) | 7.55 (6.53;8.95) | 6.41 (6.18;8.3) | 0.094989 |
| Estradiol (150.0–450.0, pmole/L) | 154.5 (100.05;206.01) | 165.75 (145.25;230) | 0.32861 |
| Gonadotropin Dosage, IU | 1725 (1293.75;1950) | 1425 (1143.75;1762.5) | 0.103318 |
| Stimulation Duration, days | 9 (8;10) | 9 (8.25;10) | 0.406869 |
| Number of follicles on the day of administration of the trigger of the final oocyte maturation | 8.5 (5;11) | 8.5 (5.25;10) | 0.986806 |
| Number of OCCs | 7 (4.25;12) | 8 (4.25;10.75) | 0.820127 |
| Number of Metaphase II (MII) Oocytes | 6 (3;9.75) | 6 (4;7.75) | 0.842485 |
| Age of Male | 34 (32;38) | 33 (31;34.75) | 0.112239 |
| Sperm Concentration, Million per Milliliter | 60 (31.25;107) | 61.5 (41;91) | 0.944129 |
| Morphologically Normal Spermatozoa, % | 2 (2;3) | 2 (1.25;3) | 0.582895 |
| Sperm with Progressive Motility, % | 56 (44;67.75) | 60 (37.5;67) | 0.904815 |
| Number of two pronuclei embryos | 5 (3;8) | 5.5 (3.25;7.5) | 0.765231 |
| Blastocyst number | 1 (1;3) | 1 (1;2.75) | 0.606454 |
| Duration of infertility | 4 (2;6) | 3 (2;5) | 0.302846 |
| Number of IVF attempts in history | 0 (0;1) | 0 (0;0.75) | 0.189145 |
1 Data are presented as a median (Me) and quartiles Q1 and Q3 in the Me format (Q1; Q3), with an indication of the statistical significance (p) using the Mann–Whitney test.
Figure 2Receiver operating characteristic (ROC) curves of the logistic regression models to predict pregnancy based on hormonal data for all women included in the study. TSH—thyroid-stimulating hormone, AMH—anti-müllerian hormone, 17_OH—17-OH-progesterone.
Small noncoding RNA deep-sequencing data for spent culture medium from morula.
| sncRNA | Spent Culture Medium from Morula without Potential for Implantation 1 | Spent Culture Medium from Morula with Potential for Implantation 1 | Culture Medium without Embryo 1 | Mann–Whitney Test ( | |||||
|---|---|---|---|---|---|---|---|---|---|
| #179 | #167 | #193 | #173 | #150 | #118 | #154 | #207 | ||
| hsa_piR_022628 | 7 | 21 | 63 | 21 | 77 | 119 | 133 | 14 | 0.00484937 |
| hsa_piR_015249 | 75 | 160 | 135 | 200 | 240 | 245 | 310 | 210 | 0.009863152 |
| hsa_piR_016735 | 23 | 107 | 171 | 124 | 205 | 232 | 265 | 204 | 0.011349613 |
| hsa_piR_004880 | 139 | 277 | 572 | 291 | 616 | 651 | 839 | 549 | 0.012957723 |
| hsa_piR_004695 | 139 | 280 | 576 | 295 | 622 | 651 | 844 | 551 | 0.013187947 |
| hsa_piR_015462 | 278 | 560 | 1152 | 590 | 1244 | 1302 | 1688 | 1102 | 0.013187947 |
| hsa_piR_000807 | 278 | 560 | 1152 | 590 | 1244 | 1300 | 1684 | 1102 | 0.01323007 |
| hsa_piR_022258 | 0 | 0 | 0 | 0 | 10 | 68 | 68 | 0 | 0.014900377 |
| hsa_piR_008112 | 2 | 0 | 8 | 2 | 9 | 7 | 9 | 0 | 0.026879189 |
| hsa_piR_019122 | 4 | 5 | 24 | 13 | 28 | 23 | 54 | 35 | 0.030210112 |
| hsa-let-7i-5p | 39 | 2 | 0 | 25 | 151 | 23 | 101 | 18 | 0.036138954 |
| hsa_piR_020365 | 9 | 15 | 12 | 27 | 19 | 53 | 40 | 9 | 0.036254562 |
| has-let-7b-5p | 37 | 2 | 7 | 33 | 160 | 29 | 95 | 17 | 0.037297033 |
| hsa_piR_015026 | 20 | 60 | 65 | 55 | 90 | 65 | 140 | 15 | 0.039937759 |
| hsa_piR_020381 | 1122 | 6942 | 5946 | 7146 | 9432 | 7413 | 14,019 | 5532 | 0.042809887 |
| hsa_piR_000765 | 540 | 432 | 300 | 565 | 1146 | 1248 | 4014 | 240 | 0.043505506 |
| hsa_piR_020497 | 170 | 122 | 189 | 140 | 246 | 165 | 223 | 296 | 0.045522073 |
| hsa_piR_002769 | 0 | 0 | 0 | 0 | 0 | 82 | 164 | 0 | 0.04660816 |
| hsa_piR_020388 | 80 | 41 | 64 | 53 | 86 | 100 | 54 | 83 | 0.115425375 |
| hsa_piR_020485 | 483 | 210 | 546 | 357 | 364 | 308 | 413 | 532 | 0.349984126 |
1 Normalized sncRNA read count.
Figure 3Principal component analysis (PCA) plot based on the sncRNA dataset for the morula stage.
Figure 4PLS-DA model for morula stage.
Figure 5Receiver operating characteristic (ROC) curves of the logistic regression models to predict implantation potential of embryo at the morula stage.
Parameters of the logistic regression model 1.
| Biomarker | AUC | Sp, % | Se, % | Cutoff | i | K |
|---|---|---|---|---|---|---|
| “hsa_piR_022258, hsa-let-7i-5p, hsa_piR_000765” | 1 | 100 | 100 | 0.5 | 67.9 | −1248.05 |
| “hsa_piR_015249, hsa_piR_022258, hsa-let-7i-5p, hsa_piR_000765” | 1 | 100 | 100 | 0.5 | −15.05 | 63.06 |
| “hsa_piR_019122, hsa_piR_022258, hsa_piR_008112, hsa_piR_000765” | 1 | 100 | 100 | 0.5 | −280.49 | −26.33 |
| “hsa_piR_019122, hsa_piR_022258, hsa-let-7i-5p, hsa_piR_000765” | 1 | 100 | 100 | 0.5 | 12.02 | 31.37 |
Figure 6Receiver operating characteristic (ROC) curves of the logistic regression models to predict the implantation potential of embryo at the blastocyst stage based on the expression level of sncRNAs associated with implantation potential of embryo at the morula stage.
SncRNA deep sequencing data for spent culture medium from blastocysts.
| sncRNA | sncRNA Read Count | Fold Changes in the sncRNA Expression Level | |||||
|---|---|---|---|---|---|---|---|
| #4 | #34 | #24 | #8 | #4/#8 | #34/#8 | #24/#8 | |
| hsa-let-7a-5p | 3835 | 443 | 1541 | 7783 | 0.493 | 0.057 | 0.198 |
| hsa-let-7b-5p | 20737 | 254 | 1834 | 26297 | 0.789 | 0.010 | 0.070 |
| hsa-let-7i-5p | 3465 | 90 | 1055 | 4072 | 0.851 | 0.022 | 0.259 |
| hsa-miR-381-3p | 120 | 1 | 83 | 475 | 0.253 | 0.002 | 0.175 |
| hsa_piR_008113 | 173 | 153 | 93 | 652 | 0.265 | 0.235 | 0.143 |
| hsa_piR_001312 | 486 | 486 | 549 | 2151 | 0.226 | 0.226 | 0.255 |
| hsa_piR_000765 | 8850 | 7248 | 2004 | 15162 | 0.584 | 0.478 | 0.132 |
| hsa_piR_016735 | 26 | 118 | 81 | 347 | 0.075 | 0.340 | 0.233 |
| hsa_piR_015249 | 175 | 625 | 580 | 280 | 0.625 | 2.232 | 2.071 |
| hsa_piR_020497 | 163 | 596 | 562 | 181 | 0.901 | 3.293 | 3.105 |
| hsa_piR_016240 | 54 | 126 | 108 | 1 | 54.000 | 126.000 | 108.000 |
| hsa_piR_016742 | 65 | 120 | 150 | 30 | 2.167 | 4.000 | 5.000 |
| hsa_piR_020485 | 2429 | 1841 | 1876 | 952 | 2.551 | 1.934 | 1.971 |
| hsa_piR_020388 | 448 | 499 | 546 | 386 | 1.161 | 1.293 | 1.415 |
Figure 7Principal component analysis (PCA) plot based on the sncRNA dataset for the blastocyst stage.
Figure 8PLS-DA model for blastocyst stage.
Figure 9Receiver operating characteristic (ROC) curves of the logistic regression model 2 to predict implantation potential of embryo at the blastocyst stage.
Parameters of the logistic regression model 2.
| Biomarker | AUC | Sp, % | Se, % | Cutoff | i | K |
|---|---|---|---|---|---|---|
| «hsa_piR_020497, | 1 | 100 | 100 | 0.5 | 1860.371618 | −1999.768215, |
| «hsa_piR_020497, | 1 | 100 | 100 | 0.5 | 1860.371618 | −1999.768215, |
| «hsa_piR_008113, | 1 | 100 | 100 | 0.5 | −6233.293319 | 6761.631563, |
| «hsa-miR-381-3p, | 1 | 100 | 100 | 0.5 | −6233.293319 | −516.0692614, |
Figure 10PLS-DA model for embryos at morula and blastocyst stages with implantation after transfer into the uterine cavity.
Figure 11Network of proteins that form physical interactions with each other for morula (A) and blastocyst (B) stages while applying the Molecular Complex Detection (MCODE) algorithm. The full name of the proteins can be found in the NCBI database (https://www.ncbi.nlm.nih.gov/gene, last accessed on 15 June 2021) according to the RefSeq mRNA accession number indicated in Table S2 (Sheet 2).
Figure 12Functional significance of sncRNA target genes that determine the implantation potential of the embryo at the morula and blastocyst stages. The sncRNA target proteins common to the morula and blastocyst stages, which are components of the networks of physically interacting proteins in Figure 10A,B, are highlighted in red.